These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22909284)

  • 1. A prospective study of health care resource utilisation and selected costs of schizophrenia in France.
    Sarlon E; Heider D; Millier A; Azorin JM; König HH; Hansen K; Angermeyer MC; Aballéa S; Toumi M
    BMC Health Serv Res; 2012 Aug; 12():269-76. PubMed ID: 22909284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health costs in anthroposophic therapy users: a two-year prospective cohort study.
    Hamre HJ; Witt CM; Glockmann A; Ziegler R; Willich SN; Kiene H
    BMC Health Serv Res; 2006 Jun; 6():65. PubMed ID: 16749921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach.
    Vázquez-Polo FJ; Negrín M; Cabasés JM; Sánchez E; Haro JM; Salvador-Carulla L
    J Ment Health Policy Econ; 2005 Sep; 8(3):153-65. PubMed ID: 16278503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European Schizophrenia Cohort (EuroSC).
    Heider D; Bernert S; König HH; Matschinger H; Hogh T; Brugha TS; Bebbington PE; Azorin M; Angermeyer MC; Toumi M
    Eur Psychiatry; 2009 May; 24(4):216-24. PubMed ID: 19328658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset.
    Laidi C; Prigent A; Plas A; Leboyer M; Fond G; Chevreul K;
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):24-36. PubMed ID: 29301707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct costs of schizophrenia in Italian community psychiatric services.
    Garattini L; Rossi C; Tediosi F; Cornaggia C; Covelli G; Barbui C; Parazzini F
    Pharmacoeconomics; 2001; 19(12):1217-25. PubMed ID: 11772157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G; Heeg B; van Hout BA; Mehnert A
    Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care resource use associated with integrated psychological treatment.
    Vasiliadis HM; Briand C; Lesage A; Reinharz D; Stip E; Nicole L; Lalonde P
    J Ment Health Policy Econ; 2006 Dec; 9(4):201-7. PubMed ID: 17200597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The daily cost of ICU patients: A micro-costing study in 23 French Intensive Care Units.
    Lefrant JY; Garrigues B; Pribil C; Bardoulat I; Courtial F; Maurel F; Bazin JÉ; ;
    Anaesth Crit Care Pain Med; 2015 Jun; 34(3):151-7. PubMed ID: 25986476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
    Mounié M; Costa N; Conte C; Petiot D; Fabre D; Despas F; Lapeyre-Mestre M; Laurent G; Savy N; Molinier L
    J Med Econ; 2020 Mar; 23(3):235-242. PubMed ID: 31876205
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cost of multiple sclerosis in France].
    Fromont A; Lehanneur MN; Rollot F; Weill A; Clerc L; Bonithon Kopp C; Binquet C; Moreau T
    Rev Neurol (Paris); 2014; 170(6-7):432-9. PubMed ID: 24856285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].
    Kuhlmann A; Mittendorf T; Hower M; Heiken H; Gerschmann S; Klauke S; Lutz T; Bogner J; Degen O; van Lunzen J; Bachmann C; Stellbrink HJ; Schmidt W; Leistner I; Mahlich J; Ranneberg B; Stoll M
    Gesundheitswesen; 2015 Jun; 77(6):e133-42. PubMed ID: 25247761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.